SpringerLink
Log in

Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy

  • Review
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Immunogenic features of some malignancies have aroused interest in immunotherapy of cancer. Immunotherapy seems most effective in patients with a small tumour burden, and the focus of immunotherapy trials has, thus, lately been on adjuvant treatment. To enable further development of immunotherapy we need to know more about the mechanisms involved in host defence, especially when the system is influenced by extrinsic factors, that is, immunomodulative agents. T lymphocytes play an important role in the host defence against tumour cells trying to escape from immune surveillance. The mechanisms that regulate the host defence systems are complex, and the influence of extrinsic factors such as immunotherapeutic agents is poorly understood. Most data on lymphocyte subsets in malignant disease originate from melanoma or renal cell carcinoma (RCC) studies, although there are scattered data on lymphocyte subsets also in other malignancies. There are several studies implying that the relative amount of CD4+, CD8+, and natural killer (NK) cells may be important and that, by reducing the tumour burden or by using different therapeutic agents, we can stimulate the host defence. However, only some of these studies imply that these changes can have an impact on clinical outcome and prognosis. The findings of the studies reviewed in this paper are mostly encouraging, but whether the lymphocyte subsets have any value as prognostic markers in patients with malignancies receiving immunotherapy is still unclear. Large randomized immunotherapy trials including an observation arm give an ideal opportunity to recognize those immunological changes that are due to therapy, related to the natural host defence, or whether they have any prognostic value.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kellock T, Chambers H, Russ S. An attempt to produce immunity to malignant disease in man.Lancet 1922;1: 217–219.

    Article  Google Scholar 

  2. Strander Het al. Clinical and laboratory investigations on man: systemic administration of potent interferon to man.J Natl Cancer Inst 1973;51: 733–742.

    Article  CAS  PubMed  Google Scholar 

  3. Rosenberg SAet al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.N Engl J Med 1985;313 (23): 1485–1492.

    Article  CAS  PubMed  Google Scholar 

  4. Quesada JR, Swanson DA, Gutterman JU. Phase II study of interferon alpha in metastatic renal-cell carcinoma: a progress report.J Clin Oncol 1985;3 (8): 1086–1092.

    Article  CAS  PubMed  Google Scholar 

  5. DeKernion JBet al. The treatment of renal cell carcinoma with human leukocyte alpha-interferon.J Urol 1983;130 (6): 1063–1066.

    Article  CAS  PubMed  Google Scholar 

  6. Pyrhönen Set al. Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma.Oncology 1992;49 (1): 22–26.

    Article  PubMed  Google Scholar 

  7. Li Yet al. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.J Immunol 1994;153 (1): 421–428.

    Article  CAS  PubMed  Google Scholar 

  8. Bernengo MGet al. The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up.Cancer 1983;52 (10): 1841–1848.

    Article  CAS  PubMed  Google Scholar 

  9. Muhonen Tet al. Decreasing CD4/CD8 ratio during prolonged four-drug chemotherapy plus interferon treatment for metastatic melanoma.J Immunother 1994;15 (1): 67–73.

    Article  CAS  Google Scholar 

  10. Cascinelli Net al. The significance of conversion of skin reactivity to efficacy of bacillus Calmette-Guerin (BCG) vaccinations given immediately after radical surgery in stage II melanoma patients.Cancer Immunol Immunother 1989;28: 282–286.

    Article  CAS  PubMed  Google Scholar 

  11. Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma.J Urol 1977;118 (4): 538–542.

    Article  CAS  PubMed  Google Scholar 

  12. Kirkwood JM, Ernstoff MS. Potential applications of interferons in oncology.Semin Oncol 1986;13 (3): 48–56.

    CAS  PubMed  Google Scholar 

  13. Kwakami Y, Robbins PF. Genes coding for tumor antigens recognized by T lymphocytes. In: DeVita V, Hellman S, Roseberg SA (ed)Biologic Therapy of Cancer. 2nd edn. JB Lippincott Company: Philadelphia, 1995, pp 53–64.

    Google Scholar 

  14. Rosenberg S. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens.J Natl Cancer Inst 1996;88 (20): 1635–1644.

    Article  CAS  PubMed  Google Scholar 

  15. Boon T, Coulie PG, Van den Eynde B. Tumor antigens recognized by T cells.Immunol Today 1997;18 (6): 267–268.

    Article  CAS  PubMed  Google Scholar 

  16. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response.Science 1996;272: 50–54.

    Article  CAS  PubMed  Google Scholar 

  17. Garrido Fet al. Implications for immunosurveillance of altered HLA clas I phenotypes in human tumours.Immunol Today 1997;18 (2): 89–95.

    Article  CAS  PubMed  Google Scholar 

  18. Passlick Bet al. Expression of MHC molecules and ICAM-1 on nonsmall cell lung carcinomas: association with early lymphatic spread of tumour cells.Eur J Cancer 1996;32A (1): 141–145.

    Article  CAS  PubMed  Google Scholar 

  19. Swain S. Who does the polarizing?Curr Biol 1995;5 (8): 849–851.

    Article  CAS  PubMed  Google Scholar 

  20. Mosmann TR. Cytokine secretion patterns and cross-regulation of T cell subsets.Immunol Res 1991;10 (3–4): 183–188.

    Article  CAS  PubMed  Google Scholar 

  21. Romagnani S. The Th1/Th2 paradigm.Immunol Today (1997);18 (6): 263–266.

    Article  CAS  PubMed  Google Scholar 

  22. Sareneva Tet al. Influenza A virus-induced IFN-alpha/beta and Il-18 synergistically enhance IFN-gamma gene expression in human T cells.J Immunol 1998;160 (12): 6032–6038.

    Article  CAS  PubMed  Google Scholar 

  23. Parronchi Pet al. IL-4 and IFN (alpha and gamma) exert opposite regulatory effects on the development of cytolytic potential by Th1 or Th2 human T cell clones.J Immunol 1992;149 (9): 2977–2983.

    Article  CAS  PubMed  Google Scholar 

  24. Moretta Let al. Human natural killer cells: origin, clonality, specificity, and receptors.Adv Immunol 1994;55 (341): 341–380.

    CAS  PubMed  Google Scholar 

  25. Kovanen PE, Knuutila S, Timonen T. Requirement of CD4+ lymphocytes in IL-2-stimulated NK cell proliferation.Scand J Immunol 1995;41 (1): 70–76.

    Article  CAS  PubMed  Google Scholar 

  26. Brittenden Jet al. Natural killer cells and cancer.Cancer 1996;77: 1226–1243.

    Article  CAS  PubMed  Google Scholar 

  27. Itoh K, Platsoucas CD, Balch CM. Autologous tumorspecific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.J Exp Med 1988;168 (4): 1419–1441.

    Article  CAS  PubMed  Google Scholar 

  28. Vujanovic NLet al. Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.J Immunol 1995;154: 281–289.

    Article  CAS  PubMed  Google Scholar 

  29. van den Berg Aet al. Cellular immune activation reflects antiviral immunity and is a favorable prognostic marker in patients with cytomegalovirus infection.Transplant Proc 1993;25 (1): 1419–1420.

    PubMed  Google Scholar 

  30. Gennari Ret al. Alterations in lymphocyte subsets as prognosticators of postoperative infections.Eur J Surg 1994;161: 493–499.

    Google Scholar 

  31. Burcham Jet al. CD4% is the best predictor of development of AIDS in a cohort of HIV-infected homosexual men [see comments].Aids 1991;5 (4): 365–372.

    Article  CAS  PubMed  Google Scholar 

  32. Schlumpberger JMet al. CD8+ lymphocyte counts and the risk of death in advanced HIV infection.J Fam Pract 1994;38 (1): 33–38.

    CAS  PubMed  Google Scholar 

  33. Eoli Met al. Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationship with short-term clinical activity.J Neurol 1993;240 (2): 79–82.

    Article  CAS  PubMed  Google Scholar 

  34. Fujisawa T, Yamaguchi Y. Autologous tumor killing activity as a prognostic factor in primary resected nonsmall cell carcinoma of the lung.Cancer 1997;79 (3): 474–481.

    Article  CAS  PubMed  Google Scholar 

  35. Garcia-Sanz Ret al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.Br J Haematol 1996;93 (1): 81–88.

    Article  CAS  PubMed  Google Scholar 

  36. San Miguel Jet al. Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies.Br J Haematol 1992;80 (3): 305–309.

    Article  CAS  PubMed  Google Scholar 

  37. Kaver Iet al. T lymphocyte subsets and function in the peripheral blood of patients with urological cancer.Oncology 1992;49 (2): 108–113.

    Article  CAS  PubMed  Google Scholar 

  38. Bernengo MGet al. T-cell subsets in melanoma patients evaluated by anti-T-cell monoclonal antibodies.Thymus 1983;5: 223–233.

    CAS  PubMed  Google Scholar 

  39. Dadian Get al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy.Br J Urol 1994;74 (1): 15–22.

    Article  CAS  PubMed  Google Scholar 

  40. LeFever AV, Funahashi A. Phenotype and function of natural killer cells in patients with bronchogenic carcinoma.Cancer Res 1991;51 (20): 5596–5601.

    CAS  PubMed  Google Scholar 

  41. Schantz SP, Campbell BH, Guillamondegui OM. Pharyngeal carcinoma and natural killer cell activity.Am J Surg 1986;152 (4): 467–474.

    Article  CAS  PubMed  Google Scholar 

  42. Taketomi Aet al. Natural killer cells activity in patients with hepatocellular carcinoma.Cancer 1998;83: 58–63.

    Article  CAS  PubMed  Google Scholar 

  43. Reinherz EL, Schlossman SF. Regulation of immune response-inducer and suppressor T-lymphocyte subsets in human beings.New Engl J Med 1980;303 (7): 370–373.

    Article  CAS  PubMed  Google Scholar 

  44. Lee K-Yet al. Immunoregulatory effects of CD4+ T helper subsets in human melanoma.Surgery 1995;117: 365–372.

    Article  CAS  PubMed  Google Scholar 

  45. Pastorfide GCet al. Image analysis of stage 1 melanoma (1.00–2.50 mm): lymphocytic infiltrates related to metastasis and survival.J Cutan Pathol 1992;19 (5): 390–397.

    Article  CAS  PubMed  Google Scholar 

  46. Rubin JTet al. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans?.Cancer Res 1989;49: 7086–7092.

    CAS  PubMed  Google Scholar 

  47. Schneeberger A, Koszik F, Stingl G. Immunologic host defense in melanoma: Delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy.J Invest Dermatol 1995;105 (Suppl): S110-S116.

    Article  Google Scholar 

  48. Tefany FJet al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma.J Invest Dermatol 1991;97 (2): 197–202.

    Article  CAS  PubMed  Google Scholar 

  49. Clark WHJet al. Model predicting survival in stage I melanoma based on tumor progression.J Natl Cancer Inst 1989;81: 1893–1904.

    Article  PubMed  Google Scholar 

  50. Clemente CGet al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.Cancer 1996;77: 1303–1310.

    Article  CAS  PubMed  Google Scholar 

  51. Kowalczyk Det al. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma.Br J Urol 1997;80 (4): 543–547.

    Article  CAS  PubMed  Google Scholar 

  52. Igarashi Tet al. Changes on distribution of CD4+/CD45RA-and CD8+/CD11-cells in tumor-infiltrating lymphocytes of renal cell carcinoma associated with tumor progression.Eur Urol 1992;22 (4):323–328.

    Article  CAS  PubMed  Google Scholar 

  53. Naito Yet al. CD8+T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.Cancer Res 1998;58: 3491–3494.

    CAS  PubMed  Google Scholar 

  54. Simony Jet al. Characterization of proliferative cells in malignant melanomas and their inflammatory infiltrates.Cancer Detect Prev 1991;15 (3): 183–187.

    CAS  PubMed  Google Scholar 

  55. Hernberg Met al. Prognostic implications of biomarkers in malignant melanoma.Melanoma Res 1998;8(3):283–291.

    Article  CAS  PubMed  Google Scholar 

  56. Grups JW, Frohmuller HG. Influence of cyclic interferon gamma on lymphocytes and their subpopulations in patients with renal carcinoma.Urology 1990;35 (2): 111–113.

    Article  CAS  PubMed  Google Scholar 

  57. Karavodin LM, Golub SH. Systemic administration of human leukocyte interferon to melanoma patients. III. Increased helper: suppressor cell ratios in melanoma patients during interferon treatment.Natl Immun Cell Growth Regul 1983;3 (4): 193–202.

    Google Scholar 

  58. Hersey Pet al. Comparative study on the effects of recombinant alpha-2 interferon on immune function in patients with disseminated melanoma.J Biol Response Mod 1986;5 (3): 236–249.

    CAS  PubMed  Google Scholar 

  59. Hersey Pet al. Effects of recombinant leukocyte interferon (rIFN-alpha A) on tumour growth and immune responses in patients with metastatic melanoma.Br J Cancer 1985;51 (6): 815–826.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Aulitzky WEet al. Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer.J Interferon Res 1989;9 (4): 425–433.

    Article  CAS  PubMed  Google Scholar 

  61. Kirkwood JMet al. In vivo biological response to recombinant interferon-gamma during a phase I dose-response trial in patients with metastatic melanoma.J Clin Oncol 1990;8 (6): 1070–1082.

    Article  CAS  PubMed  Google Scholar 

  62. Aulitzky WEet al. Low-dose gamma-interferon therapy is ineffective in renal cell carcinoma patients with large tumour burden.Eur J Cancer 1994;30A (7): 940–945.

    Article  CAS  PubMed  Google Scholar 

  63. Rimassa Let al. A new immunotherapy with rHu il-12 for metastatic melanoma.European Society of Medical Oncology, Vienna, 1996: Abstract 62.

  64. Göhring Bet al. Prognostic value of the immunomonitoring of patients with renal cell carcinoma under therapy with IL-2/IFN-alpha-2 in combination with 5-FU.Urol Res 1996;24 (5): 297–303.

    Article  PubMed  Google Scholar 

  65. Atzpodien Jet al. Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2.Tumour Biol 1993;14 (6): 354–359.

    Article  CAS  PubMed  Google Scholar 

  66. Bernengo MGet al. Changes in T and B lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma.Int J Tissue React 1984;6 (6): 505–511.

    CAS  PubMed  Google Scholar 

  67. Bast RJet al. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes.Clin Immunol Immunopathol 1983;28 (1): 101–114.

    Article  PubMed  Google Scholar 

  68. Berd D, Mastrangelo MJ. Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells.Cancer Res 1988;48 (6): 1671–1675.

    CAS  PubMed  Google Scholar 

  69. Hoon DSet al. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.Cancer Res 1990;50 (17): 5358–5364.

    CAS  PubMed  Google Scholar 

  70. Cheson BD. Infectious and immunosuppressive complications of purine analog therapy.J Clin Oncol 1995;13: 2431–2448.

    Article  CAS  PubMed  Google Scholar 

  71. Mackall CLet al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer.Blood 1994;84 (7): 2221–2228.

    Article  CAS  PubMed  Google Scholar 

  72. Takaue Yet al. Regeneration of immunity and varicellazoster virus infection after high-dose chemotherapy and peripheral blood stem cell autografts in children.Bone Marrow Transplant 1994;14: 219–223.

    CAS  PubMed  Google Scholar 

  73. Hernberg Met al. The CD4+/CD8+ ratio as a prognostic factor in patients treated with chemo-immunotherapy with metastatic melanoma.J Clin Oncol 1996;14: 1690–1696.

    Article  CAS  PubMed  Google Scholar 

  74. Hernberg M, Muhonen T, Pyrhönen S. Can the CD4+/CD8+ ratio predict the outcome of interferon-alpha therapy for renal cell carcinoma?Ann Oncol 1997;8: 71–77.

    Article  CAS  PubMed  Google Scholar 

  75. Håkansson Aet al. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment.Br J Cancer 1996;74: 670–676.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Studnicka Met al. Peripheral blood lymphocyte subsets and survival in small-cell lung cancer.Chest 1994;105 (6): 1673–1678.

    Article  CAS  PubMed  Google Scholar 

  77. Galligioni Eet al. Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus Calmette-Guerin: five-year results of a prospective randomized study.Cancer 1996;77 (12): 2560–2566.

    Article  CAS  PubMed  Google Scholar 

  78. van Bezooijen RLet al. Prognostic markers for survival in patients with metastatic renal cell carcinoma treated with interleukin-2.Cancer Immunol Immunother 1996;43 (5): 293–298.

    Article  PubMed  Google Scholar 

  79. Garbe C, Krasagakis K. Effects of interferons and cytokines on melanoma cells.J Invest Dermatol 1993;100 (Suppl 2): S239-S244.

    Article  Google Scholar 

  80. Knop J. Immunologic effects of interferon.J Invest Dermatol 1990;95 (6): 72S-74S.

    Article  CAS  PubMed  Google Scholar 

  81. Hernberg Met al. Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy.J Immunother 1997;20 (6): 488–495.

    Article  CAS  PubMed  Google Scholar 

  82. Markovic SN, Murasko DM. Role of natural killer and T-cells in interferon induced inhibition of spontaneous metastases of the B16F10L murine melanoma.Cancer Res 1991;51 (4): 1124–1128.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Division of Oncology, Helsinki University Central Hospital, P.O. Box 180, 00029, HUCH, Finland

    Micaela Hernberg

Authors
  1. Micaela Hernberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Micaela Hernberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hernberg, M. Lymphocyte subsets as prognostic markers for cancer patients receiving immunomodulative therapy. Med Oncol 16, 145–153 (1999). https://doi.org/10.1007/BF02906126

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02906126

Keywords

Search

Navigation